Scientists from Alnylam teamed with MIT researchers to develop a new nanoparticle platform with which to better deliver the genetic material to the liver. With MIT professor Robert Langer as one of its authors, the team published a paper in the journal Proceedings of the National Academy of Sciences highlighting its particles, which are inspired by the vehicles the body uses to transport cholesterol.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
San Diego-based Arcturus Therapeutics added some juice to the RNAi buzz this week at the J.P. Morgan Healthcare Conference with results from a preclinical study that showed a hefty knockdown of the genetic disease transthyretin-mediated amyloidosis.
While Roche and Sanofi are expanding their investments in RNAi, Merck is getting out.
Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's lead drug along with a portfolio of current and prospective therapies.
Back in 2006, Andrew Fire and Craig Mello won the Nobel Prize in Physiology or Medicine for their discovery of RNA interference in "silencing" genes. Today, nearly a decade later, the technology is still in limbo due to difficulties delivering the genetic material to cells.
After earlier this month announcing promising new data supporting its genetic treatment for hepatitis B, Arrowhead Research is moving forward with the candidate, submitting its application to begin a Phase IIa trial of ARC-520, which uses its polymer-based method to effectively deliver RNAi to the nucleus.
Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.
San Diego RNAi specialist Arcturus Therapeutics pulled in $5 million this week to support its RNAi tech, which it acquired earlier this year from Marina Biotech, and its own nanoparticle delivery platform. The company expects to unveil its novel gene-silencing drugs with a candidate early next year.
This week, Arrowhead Research announced the completion of its enrollment for a Phase I RNAi-based hepatitis B trial as well as a planned $60 million private offering.